ArticleBMC infectious diseases2025
A single-center retrospective analysis of serological and molecular findings in patients infected with Epstein-Barr virus.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Epstein-Barr virus based biomarkers and targeted therapies in nasopharyngeal carcinoma: a narrative review.The Lancet regional health. Western Pacific · 2026Review
- Development of a prediction model for infectious mononucleosis using machine learning algorithms based on blood cell analysis parameters.BMC infectious diseases · 2026Article
- A CRISPR-Cas13a-based two-step assay combined with lateral flow strips for rapid detection of Epstein-Barr virus.Frontiers in microbiology · 2026Article
- Development and Validation of a Nomogram Model for Predicting Non-keratinizing Nasopharyngeal Carcinoma by Combining Sex and Three EB Virus Antibodies.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This retrospective study analyzed serological and molecular diagnostic data from 7,170 EBV-infected patients treated at the Clinical Laboratory Center of Lanzhou University Second Hospital between 2018 and 2024. The aim was to evaluate the clinical utility of combining EBV DNA quantification via qPCR with antibody testing (VCA-IgM, VCA-IgG, EA-IgM, EBNA-IgG, and VCA-IgA) using ELISA. Significant age-related variations were observed across DNA replication groups, with the high viral load (1 × 10⁵ copies/mL) predominantly detected in adolescents (median age: 13 years). VCA-IgM demonstrated the strongest association with DNA replication levels (OR = 0.168, p < 0.001), yet 45.2% (14/31) of high viral load(1 × 10⁵ copies/mL) cases were VCA-IgM negative, underscoring the limitations of relying solely on serology in immunocompromised populations. Our findings emphasize the necessity of integrating molecular and serological testing for accurate EBV diagnosis, particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.